• 19
  • 5
  • Favorite

Biotech firm Roivant Sciences to go public via $7.3 billion SPAC deal

Reuters2021-05-03

(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR & Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.

The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.

Investors including Fidelity Management & Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.

After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.

SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment5

  • LemonTrader
    ·2021-05-04
    Hi
    Reply
    Report
  • ONGEE
    ·2021-05-03
    Tq
    Reply
    Report
  • belle111
    ·2021-05-03
    Wow
    Reply
    Report
  • LBear
    ·2021-05-03
    Good... pls like and respond to my comment
    Reply
    Report
  • Gab_Boey
    ·2021-05-03
    Latest
    Reply
    Report
 
 
 
 

Most Discussed

 
 
 
 
 

7x24

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email:uservice@ttm.financial